PatientsVille.com Logo


Basiliximab Medical Research Studies

Up-to-date List of Basiliximab Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Basiliximab Medical Research Studies

Rank Status Study
1 Unknown  Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
Conditions: Reduction in Sequelae Related to Calcineurin Inhibitors;   Chimeric Antibody Sensitization;   Allograft Rejection
Intervention: Drug: Basiliximab
Outcome Measures: To evaluate the risk of sensitization against the chimeric antibody, Simulect.;   To describe the pharmacokinetics of Simulect over the study course.;   To determine the absolute and relative number of CD25 receptors on T cells at the end of each dosing interval.;   To assess the difference in calculated and measured GFR.;   To assess the difference in biopsy proven acute rejection rates and the acute and chronic parameters (chronic allograft injury) on surveillance biopsies.;   To assess the difference in vital signs and lab abnormalities;   To determine the difference in incidence and severity of albuminuria/proteinuria;   To collect safety data on infections and malignancies
2 Recruiting Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Conditions: Graft Versus Host Disease;   Steroid Refractory GVHD;   Acute GVH Disease
Intervention: Drug: Infliximab and Basiliximab
Outcome Measure: Treatment
3 Recruiting Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver Transplantation
Condition: Liver Transplantation
Intervention: Drug: Basiliximab
Outcome Measures: To evaluate renal recovery/ function following OLT in patients undergoing orthotopic liver transplant at 6 and 12 months post-transplant.;   To determine the tolerability during the first year post-transplant and to determine incidence and severity acute rejection episodes
4 Recruiting Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Condition: Malignant Neoplasms Brain
Interventions: Biological: RNA-loaded dendritic cell vaccine;   Drug: Basiliximab
Outcome Measures: Functional capacity of CD4+,CD25+, CD127- T-regulatory cells;   Safety
5 Not yet recruiting ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF
Condition: Kidney Transplantation
Interventions: Drug: Anti-Thymocyte Globulins treatment;   Drug: Basiliximab treatment
Outcome Measures: Occurrence of a delayed graft function;   Duration of the delayed graft function;   Evolution of estimated glomerular filtration rate (eGFR);   Number of dialysis procedures performed after transplantation without taking into account the dialysis due to hyperkaliemia and/or hyperhydratation;   Evolution of Tacrolimus levels (T0) from Day 1 to Day 7 post transplantation then every 2 days until hospital discharge.;   Hematologic effect within the first 3 months of surgery (WBC monitoring, CD3, CD4, CD8, CD19, NK and platelet sub population analysis).;   Occurrence of infections within the first 3 months post transplantation, especially the CMV and BK reactivation assessed by RTPCR;   Occurrence of biopsy-confirmed acute rejection episodes and subclinical acute rejection episodes within the first 3 months post transplantation.;   Percentage of renal fibrosis on a surveillance kidney biopsy at 3 months post transplantation
6 Recruiting Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
Condition: Recurrent Adult Hodgkin Lymphoma
Interventions: Biological: Basiliximab;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: yttrium Y 90-labeled Basiliximab
Outcome Measures: RP2D of Yttrium-90 labeled Basiliximab (phase I);   DLT (phase I);   Anti-tumor activity of the regimen, as assessed by PFS (phase II);   ORR (phase I);   Biodistribution/analyses of Basiliximab (phase I);   Overall survival (phase II);   ORR: CR + PR (phase II);   Response duration (phase II);   Toxicities and complications (phase II)
7 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: Basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
Outcome Measures: Comparison of peptide specific immunologic response between regimens;   Comparison of regulatory T cells (Treg) number changes between regimens;   Molecular response in terms of WT1 expression;   Relapse-free survival
8 Unknown  Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
Conditions: Liver Transplantation;   Chronic Renal Insufficiency
Interventions: Drug: Basiliximab (Simulect);   Drug: Myfortic;   Drug: everolimus;   Drug: Prednisolone
Outcome Measures: Steroid resistant rejection;   Liver function;   Calculated glomerular filtration rate;   Patient survival;   Number of days on renal replacement therapy;   Graft survival
9 Unknown  Basiliximab for the Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
Conditions: Graft vs Host Disease;   Hematopoietic Stem Cell Transplantation
Interventions: Drug: Basiliximab;   Drug: Placebo
Outcome Measures: Resolution of GVHD by Day 12;   Duration and grading of acute GVHD;   Total dose of steroid and immunosuppresant;   Mortality, GVHD-related and all cause
10 Recruiting Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
Condition: Disorder Related to Renal Transplantation
Interventions: Drug: Basiliximab, Tacrolimus, MMF, Prednisolon;   Drug: Basiliximab, Tacrolimus, MMF;   Drug: Tacrolimus, MMF, rATG
Outcome Measures: Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.;   Rate of patients with steroid-free immunosuppression;   patient and graft survival rate;   graft function (calculated by the Cock- croft-Gault and MDRD-IV formula respectively calculated creatinine clearance by the Nankivell formula respectively cystatin C measurement);   Number of steroid-resistant rejections;   blood pressure level and also amount and types of blood pressure medications;   Lipid levels and also amount and types of lipid-lowering medications;   body weight, relative weight gain [kg], BMI;   infection rate, infection type and infection severity;   anemia requiring erythropoietin treatment;   PTLD incidence;   tumor incidence;   incidence of diabetes mellitus nd incidence of abnormal fasting blood sugar levels respectively incidence of impaired glucose tolerance, incidence of de novo insulin-requiring or oral-antidiabetic-requiring treatment over ≥30 days;   incidence of cataracts;   incidence of avascular necrosis;   incidence of osteoporosis;   Wound healing disorders;   incidence of chronic allograft nephropathy (CAN) (12-month histology);   incidence of CMV disease (qPCR >1000 copies/μL);   incidence of BKV disease (qPCR >1000 copies/μL);   incidence of EBV disease (qPCR >1000 copies/μL)
11 Unknown  EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function
Condition: Kidney Transplant
Intervention: Drug: Basiliximab
Outcome Measures: To compare the annualised change in GFR (delta GFR) at three and twelve months after baseline.;   To demonstrate that the efficacy of Basiliximab compared to the efficacy of tacrolimus kis comparable in the prevention of acute cellular rejection at 3 and 12 months after baseline.
12 Recruiting Safety and Efficacy of a Steroid-free, Calcineurin Inhibitor-free, Belatacept-based Immunosuppressive Regimen
Conditions: Kidney Transplantation;   Transplantation
Interventions: Biological: Anti-thymocyte Globulin (Rabbit);   Biological: Belatacept;   Drug: Methylprednisolone;   Biological: Basiliximab;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus
Outcome Measures: Mean estimated glomerular filtration rate (eGFR) calculated for each treatment group using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI);   The incidence of clinically suspected and biopsy proven acute rejection within the first 52 weeks as defined by histologic evidence of rejection and graft dysfunction.;   Proportion of subjects with estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI);   Change in chronic kidney disease (CKD) stages from baseline.;   Proportion of subjects with defined chronic kidney disease (CKD) stage 4 or 5.;   Mean calculated estimated glomerular filtration rate (eGFR) using modification of diet in renal disease (MDRD) 4 variable model.;   The slope of estimated glomerular filtration Rate (eGFR) by chronic kidney disease epidemiology collaboration equation (CKD-EPI) over time based on serum creatinine collected at all visits indicated on the schedule of events;   The incidence of delayed graft function;   The incidence of acute cellular rejection grade equal to or > than IA, by the Banff 2007 criteria, within the first 52 weeks.;   The severity of first and highest grade of acute cellular rejection within the first 52 weeks;   The incidence of antibody mediated rejection;   The type of treatment of rejection.;   The prevalence of de novo anti-donor histocompatibility antigen (HLA) antibodies;   The incidence of new onset diabetes after transplant (NODAT) or impaired fasting glucose (IFG)based on criteria specified by the ADA and WHO;   The incidence of treated diabetes between day 14 and week 52;   Hemoglobin A1c (HbA1c) measurements;   Standardized blood pressure measurement and use of anti-hypertensive medications;   Fasting lipid profile (total cholesterol, non-high density lipoprotein cholesterol, low-density lipoprotein, high density lipoprotein, and triglyceride) and use lipid lowering medications;   Total daily prescribed pill count;   The incidence of death or graft loss.;   The incidence of rejection.;   The incidence of all adverse events (AEs) and serious adverse events (SAEs);   The incidence of infections requiring hospitalization, or systemic therapy;   The incidence of BK Polyoma Virus (BKV) and Cytomegalovirus (CMV) viremia (local center monitoring);   The incidence of Epstein Barr Virus (EBV) infection as reported on the case report form;   The incidence fever > 39 degrees and blood pressure < 90mm Hg within 24 hours of onset of transplant procedure
13 Recruiting Thymus Transplantation Safety-Efficacy
Conditions: Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
Interventions: Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
Outcome Measures: Survival;   Descriptive Study - Immune Outcomes;   Naive CD 4 T Cell Count;   Descriptive Study - GVHD;   Descriptive Study - Infections;   Descriptive Study - Autoimmune Disease;   Descriptive Study - Persistent Rashes;   Descriptive Study - Thymus Donor T Cell Presence;   Descriptive Study - Other Adverse Events
14 Not yet recruiting Thymoglobulin Induction in Kidney Transplant Recipients
Conditions: Kidney Transplantation;   Ischemia-Reperfusion Injury
Interventions: Drug: antithymocyte globulin;   Drug: Basiliximab
Outcome Measures: delayed graft function;   steroid avoidance;   lymphocyte repopulation
15 Recruiting Stem Cell Transplantation for Patients With Multiple Myeloma
Condition: Myeloma
Interventions: Drug: G-CSF;   Drug: Plerixafor;   Procedure: Apheresis;   Drug: Melphalan;   Procedure: Stem cell re-infusion;   Drug: Basiliximab;   Device: CliniMACS CD25 microbeads and cell sorter
Outcome Measures: Purity of ex vivo depleted regulatory T cells prior to autologous stem cell transplant (arm 3 only);   Timing and duration of regulatory T cell depletion and recovery following autologous stem cell transplant;   Incidence of autologous graft-versus-host disease following in vivo or ex vivo regulatory T cell depletion;   Kinetics of recovery of peripheral blood cellular elements;   Number of patients that experience a complete response following autologous stem cell transplant based upon the assigned study arm using International Myeloma Working Group definitions
16 Recruiting Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Drug: Basiliximab;   Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
Outcome Measures: Change in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R);   Change in Slow Vital Capacity (SVC);   Change in Hand-Held Dynamometry (HHD);   Change in Cytokine levels in Cerebrospinal Fluid (CSF);   Collection of peripheral blood mononuclear cells (PBMCs) in Blood;   Change in Left Grip Strength;   Change in Right Grip Strength;   Change in Antibody levels in Cerebrospinal Fluid (CSF);   Collection of Ribonucleic Acid (RNA) in Blood
17 Recruiting Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
Condition: Renal Transplantation
Interventions: Drug: cyclosporine;   Drug: Everolimus
Outcome Measures: To assess if superior graft function (GFR difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de novo kidney transplant patients treated with Myfortic-everolimus plus steroids compared to Myfortic-cyclosporine.;   To compare the evolution of graft function (estimated GFR by means of modified MDRD formula)during the first 5 years post transplantation.
18 Recruiting Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen
Conditions: Renal Insufficiency;   Kidney Transplantation
Intervention: Drug: tacrolimus OD, mycophenolic acid, prednisolone
Outcome Measures: renal function parameters;   tubular atrophy and interstitial fibrosis;   rejection episodes;   graft and patient survival;   cardiovascular incidents;   infectious complications;   dexa bone densitometry
19 Recruiting Multi-peptide Vaccine With Basilixumab for Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Biological: hTERT
Outcome Measure: Number of Adverse Events
20 Recruiting Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients
Condition: Pharmacokinetics Study in de Novo Kidney Transplantation
Interventions: Drug: Simulect;   Drug: Steroids;   Drug: Prograf;   Drug: Tacrolimus Hexal
Outcome Measures: measured by dose normalized AUC 0-12 h;   Change of GFR over time and between the two groups;   Number of BPAR, graft loss or death

These studies may lead to new treatments and are adding insight into Basiliximab etiology and treatment.

A major focus of Basiliximab research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Basiliximab